BOSTON — Patients with non-BRCA gene mutations undergoing risk-reduction surgery to prevent tubo-ovarian cancers showed no signs of tubo-ovarian high-grade serous carcinoma or serous tubal intraepithelial carcinoma compared with about 3% incidence of these carcinomas in patients with BRCA mutations in a multi-center study.
“We need to define the role of risk-reduction surgery in reducing tubo-ovarian cancer risk for non-BRCA gene mutations to balance the benefit of cancer risk reduction with the risks associated with unnecessary surgery,” said first study author Aysha Mubeen, MD, an assistant professor of pathology at The University of New Mexico, in Albuquerque, New Mexico.
Bilateral salpingo-oophorectomy surgery to remove healthy ovaries and fallopian tubes is an established prophylactic measure utilized to…